Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Telomir Pharmaceuticals, Inc. (TELO) had Normalized Pre-Tax Income of $-1.72M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-47.84M |
|
-- |
|
-- |
|
$1.76M |
|
$-1.76M |
|
$0.04M |
|
$-1.72M |
|
|
Normalized Pre-Tax Income |
$-1.72M |
$-1.72M |
|
$-1.72M |
|
$-1.72M |
|
$-1.72M |
|
$-1.76M |
|
$-1.76M |
|
60.84M |
|
60.84M |
|
$-0.79 |
|
$-0.79 |
|
| Balance Sheet Financials | |
$5.37M |
|
-- |
|
-- |
|
$5.37M |
|
$0.33M |
|
-- |
|
-- |
|
$0.33M |
|
$5.03M |
|
$5.03M |
|
$5.03M |
|
68.78M |
|
| Cash Flow Statement Financials | |
$-2.79M |
|
-- |
|
$0.67M |
|
$7.29M |
|
$5.17M |
|
$-2.12M |
|
$0.83M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
16.14 |
|
-- |
|
-- |
|
-- |
|
0.03 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-2.79M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-34.20% |
|
-34.20% |
|
-32.08% |
|
-34.20% |
|
$0.07 |
|
$-0.05 |
|
$-0.05 |
|